Bayer is on the brink of filing a new MRI contrast agent for approval that can reduce levels of gadolinium, a rare earth metal that can have health and environmental consequences. The company has ...
The magnetic resonance imaging (MRI) contrast agent – based on gadobutrol – has been cleared by the FDA for cardiac MRIs on the back of two phase 3 trials which showed it was safe and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback